FIELD: medicine.SUBSTANCE: invention represents a pharmaceutical composition for treating HIV infection as a solid dosage form containing at least one HIV protease inhibitor in a therapeutically effective amount specified in a group of nelfinavir sacvinavir tipranavir darunavir indinavir ritonavir lopinavir palinavir or fosamprenavir and pharmaceutically acceptable additives differing by the fact that the pharmaceutically acceptable additives are presented by at least one water-soluble polymer i...

The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-14-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease...

Activated haptens useful for generating immunogens to HIV protease inhibitors immunogens useful for producing antibodies to HIV protease inhibitors and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir nelfinavir amprenavir ritonavir a...

La invención incluye métodos composiciones y kits útiles para el tratamiento de una infección viral mediante la administración de ácido ácido 6-(3-cloro-2- fluorobencil)-1-[(2S)-1-hidroxi-3-metilbutan-2-iI]-7-metoxi-4-oxo-14-dihidroquinolin-3-carboxílico o una sal farmacéuticamente aceptable del mismo con atazanavir o una sal farmacéuticamente aceptable del mismo y opcionalmente con un compuesto que inhibe el citocromo P-450 o una sal farmacéuticamente aceptable del mismo. 1.- Una com...

The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-14-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent.In some embodiments of the present invention the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease ...

PROBLEM TO BE SOLVED: To provide a liquid pharmaceutical composition for treatment of AIDS having improved oral bioavailability for compounds which are inhibitors of HIV protease.SOLUTION: The liquid pharmaceutical composition comprises (a) the HIV protease inhibitor (b) an organic solvent comprising a mixture of a long chain fatty acid and an alcohol (c) a surfactant wherein the liquid preparation is encapsulated in either hard gelatin capsules or soft elastic capsules (SEC). The HIV protease i...

Activated haptens useful for generating immunogens to HIV protease inhibitors immunogens useful for producing antibodies to HIV protease inhibitors and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir nelfinavir amprenavir ritonavir a...